In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Zyvox Study Of Catheter-Related Infections May Lower Enrollment Goal

Executive Summary

Pfizer may change its enrollment goal for a Zyvox study depending on FDA's modification of its 1999 guidance on catheter-related bloodstream infections (CRBSI)

You may also be interested in...



Pfizer $1.9 Bil. Vicuron Acquisition Culminates Antibiotic Research Deal

Pfizer's $1.9 bil. purchase of Vicuron marks the culmination of a six-year collaboration between the pharma giant and the biotech company to develop new antibiotic candidates

Pfizer $1.9 Bil. Vicuron Acquisition Culminates Antibiotic Research Deal

Pfizer's $1.9 bil. purchase of Vicuron marks the culmination of a six-year collaboration between the pharma giant and the biotech company to develop new antibiotic candidates

FDA Moving Forward On Primary Bacteremia Indication

FDA will continue work on defining an indication for primary bacteremia due to Staph aureus (PBSA) after the agency found support for the claim from the Anti-Infective Drugs Advisory Committee

Related Content

UsernamePublicRestriction

Register

PS044979

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel